BioAmber (NYSE: BIOA) reported Q4 EPS of ($0.40), $0.05 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $1.11 million versus the consensus estimate of $830 thousand.

For earnings history and earnings-related data on BioAmber (BIOA) click here.